Neoadjuvant therapy as a platform for drug development: Current controversies and regulatory perspectives

Laleh Amiri-Kordestani; Julia A. Beaver; Patricia Cortazar

Neoadjuvant therapy as a platform for drug development: Current controversies and regulatory perspectives

Laleh Amiri-Kordestani, Julia A. Beaver, Patricia Cortazar

Research output: Contribution to journal › Article › peer-review

Abstract

This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.

Original language	English (US)
Journal	ONCOLOGY (United States)
Volume	29
Issue number	11
State	Published - Nov 15 2015
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{5a5091c9a5944f91ad18f66b00fc0abd,

title = "Neoadjuvant therapy as a platform for drug development: Current controversies and regulatory perspectives",

abstract = "This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.",

author = "Laleh Amiri-Kordestani and Beaver, {Julia A.} and Patricia Cortazar",

year = "2015",

month = nov,

day = "15",

language = "English (US)",

volume = "29",

journal = "ONCOLOGY (United States)",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "11",

}

TY - JOUR

T1 - Neoadjuvant therapy as a platform for drug development

T2 - Current controversies and regulatory perspectives

AU - Amiri-Kordestani, Laleh

AU - Beaver, Julia A.

AU - Cortazar, Patricia

PY - 2015/11/15

Y1 - 2015/11/15

N2 - This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.

AB - This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.

UR - http://www.scopus.com/inward/record.url?scp=84947247013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947247013&partnerID=8YFLogxK

M3 - Article

C2 - 26573064

AN - SCOPUS:84947247013

SN - 0890-9091

VL - 29

JO - ONCOLOGY (United States)

JF - ONCOLOGY (United States)

IS - 11

ER -

Neoadjuvant therapy as a platform for drug development: Current controversies and regulatory perspectives

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this